Understanding Cablivi Prescribing Information: What You Need to Know
Cablivi (caplacizumab), a drug developed by Ablynx, was approved in 2018 by the US Food and Drug Administration (FDA) for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), a rare blood disorder. Cablivi is a first-in-class drug, meaning that it is the first of its kind to be approved for this indication.
What is aTTP?
aTTP is a blood disorder that can lead to blood clotting in small blood vessels throughout the body. This can cause damage to organs such as the brain, kidneys, and heart. aTTP is a rare condition, affecting around 2 to 3 people per million per year. However, it can be life-threatening if not treated promptly.
How Does Cablivi Work?
Cablivi is a monoclonal antibody that targets von Willebrand factor (vWF), a protein in the blood that is involved in blood clotting. Cablivi works by preventing the binding of vWF to platelets, which in turn helps to prevent blood clotting. By doing so, Cablivi can reduce the risk of organ damage in patients with aTTP.
How is Cablivi Administered?
Cablivi is administered intravenously (via an IV) by a healthcare professional. The recommended dose is a loading dose of 10 mg followed by a maintenance dose of 10 mg daily for 30 days. Cablivi should be taken in combination with plasma exchange and immunosuppressive therapy.
What Are the Side Effects of Cablivi?
Like all drugs, Cablivi can cause side effects. The most common side effects of Cablivi include bleeding from the nose or gums, headache, and bruising. More serious side effects are rare, but can include bleeding in the brain or other organs. Patients should talk to their healthcare provider if they experience any unusual side effects while taking Cablivi.
Conclusion
Cablivi is a first-in-class drug that has been approved by the FDA for the treatment of aTTP in adults. It works by preventing the binding of vWF to platelets, which reduces the risk of organ damage. Cablivi is administered intravenously and should be taken in combination with plasma exchange and immunosuppressive therapy. While Cablivi can cause side effects, it is generally well-tolerated by patients. If you or a loved one has been diagnosed with aTTP, be sure to talk to your healthcare provider about whether Cablivi may be a suitable treatment option.
(Note: Do you have knowledge or insights to share? Unlock new opportunities and expand your reach by joining our authors team. Click Registration to join us and share your expertise with our readers.)